Dossier progressif n° 272
Publié le 8 Novembre 2023
Veuillez lire l’article suivant : Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol 2020;31(7):942-50.